CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

All Clinical Trials for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00466518 ↗	Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant	Completed	University of Nebraska	N/A	2007-04-01	This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population.
NCT00466518 ↗	Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant	Completed	University of Oklahoma	N/A	2007-04-01	This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population.
NCT01357148 ↗	A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)	Terminated	Merck Sharp & Dohme Corp.		2009-03-01	The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.
NCT03180281 ↗	Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell	Unknown status	First Affiliated Hospital Xi'an Jiaotong University	N/A	2017-07-01	Prevalence of diabetes is increasing rapidly both in China and all over the world.Hyperglycemia is an important risk factor and major hazard to cardiovascular and cerebrovascular diseases and even dangerous to human health."High glucose toxicity "cause pancreatic β cell non-physiologic and irreversible damage.It is an important cause of β cell dysfunction.High glucose toxicity further suppresses insulin secretion of β cell, further even β-cell function failure.It is urgent to explore more effective and safety treatments which can also protect islet cells function.How to release high glucose toxicity , reverse the toxic effects of hyperglycemia on islet β cells as early as possible, and to maximize recover and protect the pancreatic β cell function is the keypoints of this study.Our aim is to explore the non-inferiority of new antidiabetic drugs DPP4 inhibitors on releasing glucose toxicity and protecting islet β cell function compared with traditional treatments on newly diagnosed type 2 diabetes,compare efficacy and safety of different oral antidiabetic drugs and insulin on newly diagnosed type 2 diabetes patients with high glucose toxicity and compare differences of different oral antidiabetic drugs and insulin on protecting pancreatic β-cell function.
NCT04877106 ↗	Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects	Completed	The Affiliated Hospital of Qingdao University	Phase 1	2018-04-07	An open-label, randomized, single-dose, two-period, two-group, crossover study was conducted in 48 healthy Chinese volunteers under fasted or fed conditions (24 volunteers for each condition) to assess the bioequivalence between two formulations of Sitagliptin Phosphate/metformin Hydrochloride Tablets.
NCT06124495 ↗	Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.	Completed	Galenicum Health	Phase 1	2023-01-13	The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fasting conditions.
NCT06124547 ↗	Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.	Completed	Galenicum Health	Phase 1	2023-01-16	The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fed conditions.

Clinical Trial Conditions for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Condition Name

Condition Name for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Intervention	Trials
Diabetes Mellitus, Type 2	5
Bioequivalence	4
Type 2 Diabetes Mellitus	2
Glucotoxicity	1

Condition MeSH

Condition MeSH for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Intervention	Trials
Diabetes Mellitus, Type 2	8
Diabetes Mellitus	3

Clinical Trial Locations for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Trials by Country

Trials by Country for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Location	Trials
Mexico	4
China	3
United States	1
Pakistan	1

Trials by US State

Trials by US State for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Location	Trials
Nebraska	1

Clinical Trial Progress for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Clinical Trial Phase

Clinical Trial Phase for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
Phase 1	5

Clinical Trial Status

Clinical Trial Status for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Clinical Trial Phase	Trials
Completed	8
Terminated	1
Unknown status	1

Clinical Trial Sponsors for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Sponsor Name

Sponsor Name for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Sponsor	Trials
Galenicum Health	4
University of Nebraska	1
University of Oklahoma	1

Sponsor Type

Sponsor Type for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Sponsor	Trials
Other	7
Industry	5
NETWORK	1

Clinical Trials Update, Market Analysis, and Projection: Metformin Hydrochloride + Sitagliptin Phosphate

Last updated: May 7, 2026

What is the current clinical-trial landscape for metformin + sitagliptin?

Public interventional trial activity for the fixed-dose combination (FDC) has been limited versus single-agent programs and versus broader type 2 diabetes (T2D) cardiovascular and renal outcome studies. Most contemporary “combination” evidence in practice comes from: (1) post-authorization effectiveness and safety studies comparing FDC use versus usual care, and (2) trials that enroll metformin-treated or metformin-naïve patients and randomize add-on sitagliptin versus other comparators.

Trial pattern that dominates metformin + sitagliptin evidence

Across registries and publications, the dominant designs are:

• Add-on sitagliptin trials in patients inadequately controlled on metformin.
• Comparative effectiveness/safety trials using FDC regimens versus separate-tablet administration or versus other add-on classes (DPP-4 inhibitor comparators, GLP-1 receptor agonists, SGLT2 inhibitors, or insulin strategies depending on geography and time).
• Real-world evidence studies that evaluate persistence, adherence, hypoglycemia rates, weight change, and renal and glycemic endpoints.

Practical implication for “clinical trials update”

For an investor or R&D sponsor, the key point is that metformin + sitagliptin programs largely track the lifecycle of sitagliptin’s broad clinical evidence base rather than creating a high volume of new, combination-specific phase 3 readouts. The pipeline signal is typically incremental: formulation, titration algorithms, switching strategies, and expanded subpopulations (elderly, renal impairment strata, and comorbidity cohorts).

Where does the market sit today, and what are the demand drivers?

The metformin + sitagliptin market is driven by three demand engines:

1. Metformin’s status as foundational first-line therapy in T2D and its widespread inclusion in formularies and guidelines.
2. DPP-4 inhibitor positioning (sitagliptin in particular) as a lower-complexity escalation option when weight neutrality and low hypoglycemia risk matter.
3. FDC convenience and adherence uplift, where payer coverage and pharmacy benefit design favor fixed-dose combinations or reduced pill burden.

Market demand drivers by segment

• Commercial / primary care channel: preference for oral, once- or twice-daily regimens with modest monitoring burden.
• Formulary access dynamics: sitagliptin often competes in broad DPP-4 inhibitor tiers; metformin is commonly preferred as the backbone. When step edits exist, metformin use plus add-on sitagliptin is a common route.
• Safety and tolerability: low hypoglycemia risk relative to sulfonylureas and insulin supports use in older populations and in patients where hypoglycemia is a key concern.
• Renal impairment subset: DPP-4 inhibitors are used with dose adjustments; metformin has its own renal eligibility constraints, which shapes switching patterns and prescriber behavior.

How should you project near- to mid-term growth for metformin + sitagliptin?

A credible projection for an established FDC combination is not a “new molecule adoption curve.” It is a function of:

• Share shifts within T2D oral add-ons (DPP-4 vs SGLT2 vs GLP-1 and oral combination strategies),
• Payer movement toward agents with cardiorenal outcomes where covered,
• Generic exposure risk (metformin is generic; sitagliptin has patent-expiry-related dynamics that vary by country),
• Lifecycle management through dosing convenience, switch programs, and adherence optimization.

Projection framework (directional, action-oriented)

Use a three-layer model:

Layer 1: Total addressable market growth

• T2D prevalence and treatment intensification continue to expand the pool of patients needing add-on therapy to metformin.

Layer 2: Class share

• DPP-4 inhibitors face sustained share pressure from GLP-1 receptor agonists and SGLT2 inhibitors, especially when payers prioritize cardiorenal outcome evidence.
• DPP-4 inhibitors maintain a base in patients who need weight-neutral therapy, have contraindications to GLP-1/SGLT2, or where cost and formulary restrictions limit uptake.

Layer 3: FDC share within class

• FDCs typically maintain resilience because they reduce pill burden and help meet step-therapy and adherence targets.
• Growth is usually modest unless payer design specifically incentivizes FDC dispensing or copays compress relative to free combinations.

Base-case projection (investment-relevant interpretation)

For metformin + sitagliptin, the most likely near-term market trajectory is:

• Stable to low-growth overall revenues (not an innovation-led growth profile).
• Gradual share dilution versus outcome-driven classes where payer policies strongly favor SGLT2 and GLP-1.
• Defensive performance in markets where DPP-4 coverage remains broad and where adherence programs support oral combination persistence.

What are the regulatory and competitive vectors that will shape the next cycle?

Competition from newer standard-of-care add-ons

• SGLT2 inhibitors: payer tilt toward demonstrated cardiorenal outcome benefits drives formulary preference in many geographies.
• GLP-1 receptor agonists: expanded adoption from both weight and glycemic control angles.
• Oral combinations: fixed-dose strategies that reduce injection barriers can shift channel dynamics away from DPP-4.

Generics and pricing pressure

• Metformin is fully generic in most markets, leaving the pricing power on the DPP-4 component as the main lever.
• When sitagliptin faces generic entry, combination pricing compresses quickly; revenue performance then tracks utilization and retention rather than price growth.

What endpoints matter most for ongoing or future evidence generation?

Even when new phase 3 combo trials are not frequent, evidence needs typically cluster around:

• A1c lowering durability in metformin background therapy.
• Hypoglycemia rates and real-world safety in elderly and comorbidity populations.
• Renal function and dosing behavior (metformin eligibility and sitagliptin renal-adjusted dosing).
• Adherence and persistence with FDC versus separate dosing.

How do you use this for R&D and investment decisioning?

R&D options that create commercial differentiation

Given the class maturity, meaningful product strategy is usually:

• Formulation differentiation (improved tolerability or dosing convenience, where allowed),
• Patient- and clinician-use studies that target switch and adherence outcomes,
• Real-world evidence partnerships to support payer negotiations.

Investment diligence priorities

• U.S. and ex-U.S. patent and exclusivity status for the sitagliptin component and for any FDC formulation/line extensions.
• Generic penetration trajectory in major markets and impact on ex-manufacturer and wholesaler pricing.
• Formulary and step-therapy trends for DPP-4 add-on therapy versus preferred classes.
• Brand-to-generic migration elasticity in target countries.

Market snapshot: what to look for in 2024-2026 updates

Because metformin is generic and sitagliptin is the differentiating drug, watch:

• Revenue performance by DPP-4 share and FDC mix within T2D add-on therapy.
• Payer restrictions (prior authorization and step edits) affecting access.
• Real-world adherence metrics tied to FDC availability and copay programs.

---

Key Takeaways

• Metformin + sitagliptin clinical evidence is dominated by add-on and comparative studies rather than high-volume, new combination phase 3 readouts.
• Market demand is stable because metformin is foundational and sitagliptin supports a low hypoglycemia, oral escalation pathway.
• Projections should assume stable to low growth with class share pressure from SGLT2 and GLP-1, unless payer design and FDC incentives materially favor DPP-4.
• Next-cycle competitiveness will hinge on generic pricing compression, formulary access, and real-world persistence/adherence rather than breakthrough efficacy.

FAQs

1. Is metformin + sitagliptin still used as an add-on after metformin failure?
   Yes. It remains a common oral escalation choice where low hypoglycemia risk and weight neutrality matter and where payer coverage supports DPP-4 access.

2. Are there many new phase 3 clinical trials specifically for the fixed-dose combination?
   Public evidence activity is generally incremental, with fewer prominent new combo-specific phase 3 programs than for single-agent outcome studies.

3. What most affects the revenue outlook: metformin or sitagliptin?
   Sitagliptin. Metformin is generic in most markets, so the combination’s revenue dynamics track pricing and market share changes tied to the DPP-4 component.

4. How do SGLT2 inhibitors and GLP-1 receptor agonists influence the outlook?
   They typically take share when payers prioritize cardiorenal outcomes and/or weight-driven policies, leading to slow dilution for DPP-4 unless access remains broad.

5. What endpoints will likely matter for payer and clinician adoption going forward?
   A1c durability, hypoglycemia and tolerability, renal dosing behavior, and adherence/persistence linked to FDC use.

---

References

1. FDA. “JANUVIA (sitagliptin) Drug Label.” U.S. Food and Drug Administration.
2. FDA. “METFORMIN HYDROCHLORIDE Drug Label.” U.S. Food and Drug Administration.
3. ClinicalTrials.gov. Search results for studies involving sitagliptin in combination with metformin (accessed May 7, 2026).
4. ADA (American Diabetes Association). Standards of Care in Diabetes (current edition as of 2025).